These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
221 related articles for article (PubMed ID: 36112771)
1. BT8009; A Nectin-4 Targeting Bicycle Toxin Conjugate for Treatment of Solid Tumors. Rigby M; Bennett G; Chen L; Mudd GE; Harrison H; Beswick PJ; Van Rietschoten K; Watcham SM; Scott HS; Brown AN; Park PU; Campbell C; Haines E; Lahdenranta J; Skynner MJ; Jeffrey P; Keen N; Lee K Mol Cancer Ther; 2022 Dec; 21(12):1747-1756. PubMed ID: 36112771 [TBL] [Abstract][Full Text] [Related]
2. Discovery of BT8009: A Nectin-4 Targeting Bicycle Toxin Conjugate for the Treatment of Cancer. Mudd GE; Scott H; Chen L; van Rietschoten K; Ivanova-Berndt G; Dzionek K; Brown A; Watcham S; White L; Park PU; Jeffrey P; Rigby M; Beswick P J Med Chem; 2022 Nov; 65(21):14337-14347. PubMed ID: 36204777 [TBL] [Abstract][Full Text] [Related]
3. Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E-based Antibody-Drug Conjugate for Treatment of Nectin-4-expressing Cancers. Zhou W; Fang P; Yu D; Ren H; You M; Yin L; Mei F; Zhu H; Wang Z; Xu H; Cao Y; Sun X; Xu X; Bi J; Wang J; Ma L; Wang X; Chen L; Zhang Y; Cen X; Zhu X; Lou L; Liu D; Tan X; Yang J; Meng T; Shen J Mol Cancer Ther; 2023 Aug; 22(8):913-925. PubMed ID: 37196158 [TBL] [Abstract][Full Text] [Related]
4. Targeting nectin-4 by antibody-drug conjugates for the treatment of urothelial carcinoma. Wong JL; Rosenberg JE Expert Opin Biol Ther; 2021 Jul; 21(7):863-873. PubMed ID: 34030536 [TBL] [Abstract][Full Text] [Related]
5. Nectin-4-directed antibody-drug conjugates (ADCs): Spotlight on preclinical and clinical evidence. Khosravanian MJ; Mirzaei Y; Mer AH; Keyhani-Khankahdani M; Abdinia FS; Misamogooe F; Amirkhani Z; Bagheri N; Meyfour A; Jahandideh S; Barpour N; Nikmanesh Y; Shahsavarani H; Abdollahpour-Alitappeh M Life Sci; 2024 Sep; 352():122910. PubMed ID: 39002610 [TBL] [Abstract][Full Text] [Related]
6. Exploring membranous NECTIN-4 expression patterns and enfortumab vedotin response in prostate cancer. Weiten R; Bernhardt M; Niemann M; Kristiansen G; Grünwald V; Ritter M; Hölzel M; Eckstein M; Alajati A; Klümper N; Krausewitz P J Cell Mol Med; 2024 Jul; 28(14):e18572. PubMed ID: 39072867 [TBL] [Abstract][Full Text] [Related]
7. Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models. Challita-Eid PM; Satpayev D; Yang P; An Z; Morrison K; Shostak Y; Raitano A; Nadell R; Liu W; Lortie DR; Capo L; Verlinsky A; Leavitt M; Malik F; Aviña H; Guevara CI; Dinh N; Karki S; Anand BS; Pereira DS; Joseph IB; Doñate F; Morrison K; Stover DR Cancer Res; 2016 May; 76(10):3003-13. PubMed ID: 27013195 [TBL] [Abstract][Full Text] [Related]
8. Enfortumab Vedotin-ejfv: A First-in-Class Anti-Nectin-4 Antibody-Drug Conjugate for the Management of Urothelial Carcinoma. Halford Z; Anderson MK; Clark MD Ann Pharmacother; 2021 Jun; 55(6):772-782. PubMed ID: 32945172 [TBL] [Abstract][Full Text] [Related]
9. Clinical Pharmacology of the Antibody-Drug Conjugate Enfortumab Vedotin in Advanced Urothelial Carcinoma and Other Malignant Solid Tumors. Tang M; Garg A; Bonate PL; Rosenberg JE; Matsangou M; Kadokura T; Yamada A; Choules M; Pavese J; Nagata M; Tenmizu D; Koibuchi A; Heo N; Wang L; Wojtkowski T; Hanley WD; Poondru S Clin Pharmacokinet; 2024 Apr; 63(4):423-438. PubMed ID: 38609704 [TBL] [Abstract][Full Text] [Related]
10. Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance. Klümper N; Ralser DJ; Ellinger J; Roghmann F; Albrecht J; Below E; Alajati A; Sikic D; Breyer J; Bolenz C; Zengerling F; Erben P; Schwamborn K; Wirtz RM; Horn T; Nagy D; Toma M; Kristiansen G; Büttner T; Hahn O; Grünwald V; Darr C; Erne E; Rausch S; Bedke J; Schlack K; Abbas M; Zschäbitz S; Schwab C; Mustea A; Adam P; Manseck A; Wullich B; Ritter M; Hartmann A; Gschwend J; Weichert W; Erlmeier F; Hölzel M; Eckstein M Clin Cancer Res; 2023 Apr; 29(8):1496-1505. PubMed ID: 36534531 [TBL] [Abstract][Full Text] [Related]
11. An iodine‑labelled Antibody-drug conjugate PET probe for noninvasive monitoring of Nectin-4 expression in urothelial carcinoma. Ren Y; Liu T; Li S; Ma X; Xia L; Wang P; Guo Q; Yao Y; Hou X; Sheng X; Zhu H; Yang Z Int J Pharm; 2024 Feb; 651():123756. PubMed ID: 38160990 [TBL] [Abstract][Full Text] [Related]
12. Nectin-4: a Tumor Cell Target and Status of Inhibitor Development. Bouleftour W; Sargos P; Magne N Curr Oncol Rep; 2023 Mar; 25(3):181-188. PubMed ID: 36696077 [TBL] [Abstract][Full Text] [Related]
13. [Antibody-drug conjugates directed against NECTIN-4 as a new treatment option for patients with metastatic urothelial carcinoma]. Klümper N; Eckstein M; Kunath F; Heidegger I; Becker C; Rausch S; Urologie; 2023 Nov; 62(11):1193-1199. PubMed ID: 37658236 [TBL] [Abstract][Full Text] [Related]
14. A humanized trivalent Nectin-4-targeting nanobody drug conjugate displays potent antitumor activity in gastric cancer. Wu Y; Zhu M; Sun B; Chen Y; Huang Y; Gai J; Li G; Li Y; Wan Y; Ma L J Nanobiotechnology; 2024 May; 22(1):256. PubMed ID: 38755613 [TBL] [Abstract][Full Text] [Related]
15. Nectin-4: a Novel Therapeutic Target for Skin Cancers. Hashimoto H; Tanaka Y; Murata M; Ito T Curr Treat Options Oncol; 2022 Apr; 23(4):578-593. PubMed ID: 35312963 [TBL] [Abstract][Full Text] [Related]